MedTrace Logo

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

NCT01819922 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-05-02

Study results available
· View outcomes & findings →

Summary

This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

PF-05175157

600 mg as powder in capsule, one dose within 5 minutes prior to AM meal

DRUG

Placebo

Placebo powder in capsule, one dose within 5 minutes prior to AM meal

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01819922 on ClinicalTrials.gov